Ryoncil (remestemcel-l-rknd) — Coverage Criteria
Customize your policy alerts
Sign up for univerahealthcare Policy PHARMACY-131 alerts
Get alerted when Policy PHARMACY-131 changes without checking for updates manually.
Monitor payer policy activity
Policy governing prior authorization and medical benefit coverage for Ryoncil, an allogeneic MSC therapy for pediatric steroid‑refractory acute graft‑versus‑host disease (SR‑aGVHD); applies to multiple lines of business listed by the payer.
No material clinical or coverage changes in this revision.
Coverage Criteria for Ryoncil (remestemcel-l-rknd)
Initial Therapy — Covered when ALL of the following are met
Covered when ALL of the following are met
Continuation / Recurrence — Criteria for continued or additional treatment
Criteria for continued or additional treatment
Response evaluated 56 days after continued therapy; objective documentation required (skin BSA, bilirubin, stool volume).
Experimental/Investigational: Additional Gene/Cellular Therapy; Prior Exposure Exclusions
The following situations are considered experimental and investigational and therefore not eligible for coverage:
Includes switching between CAR-T products, switching between autologous and allogeneic cellular therapies, sequential CAR-T/TCR-T/NK-cell therapies, receiving gene therapy after prior gene/cellular therapy, and receiving an in vivo gene therapy following prior vector-based therapy.
Eligibility may require documented evidence supporting safety and anticipated benefit; absent such evidence, coverage is not supported.
Ryoncil will not be approved for uses beyond the FDA‑approved indication. Examples of excluded uses include treatment of chronic GVHD, non‑steroid‑refractory acute GVHD (non‑SR‑aGVHD), SR‑aGVHD that is not associated with allogeneic HSCT, concomitant use with other systemic first‑line or second‑line SR‑aGVHD therapies, and use in adult patients with SR‑aGVHD.
Retreatment, repeat administration, reinfusion, or sequential therapy with other gene or cellular products is generally considered experimental and investigational. The policy notes that most gene and cellular therapies are studied as one‑time interventions and that the safety, efficacy, and durability of additional administrations have not been established.
Sequential administration of an additional or different gene or cellular therapy after prior exposure is excluded as experimental and investigational. The policy explicitly includes examples such as switching between CAR‑T products, switching between autologous and allogeneic cellular therapies, sequential CAR‑T/TCR‑T/NK‑cell therapies, receiving a gene therapy after prior gene or cellular therapy exposure, and receiving an in vivo gene therapy following any prior vector‑based therapy.
Additional treatment will not be authorized for patients who had a documented No Response to the initial treatment course. Approval timeframes and dosing windows must be observed; repeat dosing outside the policy‑specified approval durations (for example, outside the stated 4‑week/28‑day approval periods for initial or repeated administration) is not authorized.
Use of an additional or different gene or cellular therapy after prior exposure is considered not supported due to insufficient evidence of anticipated clinical benefit and safety for sequential administration. Absent documented evidence demonstrating safety and anticipated benefit, individuals previously treated with any autologous cellular therapy, any allogeneic genetically modified cellular therapy, any in vivo gene therapy (e.g., AAV, lentiviral vector), or any ex vivo gene‑modified cell product are generally not eligible for additional gene or cellular therapy.
Initial Therapy Dosing and Requirements
Initial Therapy Dosing — Initial dosing schedule
Initial dosing schedule
Dose per infusion: 2 × 10^6 MSC/kg.
Continuation and Recurrence Dosing Rules
Continuation / Recurrence Dosing — Rules for continued therapy after initial response
Rules for continued therapy after initial response
Response evaluation timing: 28 days after first dose for initial treatment; objective documentation required.
Must meet recurrence timing criteria (>28 days after first infusion of initial therapy or >56 days after achieving complete response to continued therapy) and not have started another systemic SR-aGVHD therapy.
Coding and Dosage Information
| J3490 | Ryoncil |
| J3490 | Ryoncil |
Provider Responsibilities and Documentation Requirements
Obtain prior authorization for all administrations (J3490)
Prior authorization is required for Ryoncil regardless of site of administration and applies to both inpatient and outpatient settings; HCPCS J3490 is the billing code identified for Ryoncil.
- Submit a prior authorization request for any planned infusion (inpatient or outpatient).
- Use HCPCS code J3490 for billing/eligibility assessment per policy.
Prior authorization and HCPCS coding (J3490) required
Coverage and reimbursement eligibility depend on member benefits and accurate coding; prior authorization must be requested and HCPCS J3490 should be used to identify Ryoncil on claims.
- Verify member contract/benefit coverage before submission.
- Ensure HCPCS J3490 is included on claim forms to reflect the service.
Document failure/unsuitability of Jakafi and all NCCN 2A alternatives
Provider must document why ruxolitinib (Jakafi) AND all NCCN Category 2A recommended alternative therapies are not appropriate or suitable and submit a letter of medical necessity addressing organ involvement, prior treatments, comorbidities, and institutional experience.
- Include explicit rationale why Jakafi and each NCCN Category 2A alternative (e.g., ECP, basiliximab, infliximab, ATG) cannot be used.
- Attach a letter of medical necessity describing prior treatments and contraindications or unsuitability.
Do not pursue sequential gene/cellular therapies — considered experimental
Sequential or additional gene or cellular therapies after prior exposure are considered experimental and investigational and are not supported as an acceptable subsequent step following Ryoncil.
- Do not request coverage for additional or different gene/cellular therapies after prior gene/cellular therapy exposure—these requests are generally not eligible.
- Examples include switching between CAR-T products, autologous ↔ allogeneic switches, sequential CAR-T/TCR-T/NK-cell therapies, or receiving gene therapy after prior vector-based therapy.
Provide objective diagnostic and grading documentation (Glucksberg/IBMTR)
Submit objective documentation confirming diagnosis and disease grade using the modified Glucksberg or IBMTR criteria, including measures of organ involvement (for example: skin BSA, serum bilirubin, stool volume) and baseline organ assessment.
- Provide objective baseline organ involvement for all organs (including unaffected organs) at diagnosis.
- Include skin percent BSA, laboratory bilirubin values, and stool volume (mL/day) as applicable.
Submit supporting clinical documentation and prior treatment history
Include supporting clinical documentation for the indication and prior treatment history—progress notes, diagnostic testing, labs, and references to prescribing information or clinical studies may be used to justify the request.
- Attach progress notes documenting prior steroid treatment and timing that meets steroid‑refractory definition.
- Supply relevant lab results, imaging, genetic/biomarker tests, and citations to prescribing information or pivotal trial data as needed.
Denial risk for missing documentation or off‑label/unapproved uses
Requests missing required clinical documentation or seeking off‑label uses (for example chronic GVHD, adult patients, SR‑aGVHD not associated with allogeneic HSCT, or concurrent use with other systemic first‑ or second‑line therapies) may be denied.
- Incomplete baseline or response documentation may prevent evaluation and lead to denial.
- Avoid submitting requests for indications or patient populations explicitly excluded by the policy.
Prior gene/cellular therapy exposure must be reported — may preclude coverage
Prior exposure to any gene or cellular therapy (autologous cellular therapy, any allogeneic genetically modified cellular therapy, any in vivo gene therapy, or any ex vivo gene‑modified cell product) generally renders an individual ineligible for additional gene/cellular therapy and may trigger denial.
- Disclose any prior autologous therapies (e.g., CAR‑T, TCR‑T, TIL), allogeneic genetically modified cellular therapies, or prior in vivo/ex vivo gene therapies in the submission.
- Provide documented evidence supporting safety and anticipated benefit if considering another gene/cellular therapy despite prior exposure; absent such evidence, coverage is not supported.
Step Therapy Requirements
| Requirement | Details |
|---|---|
| Step therapy requirement | Provider must document why ruxolitinib (Jakafi) AND all NCCN Category 2A recommended alternative therapies for steroid‑refractory acute GVHD (for example: ECP, basiliximab, infliximab, ATG) are not appropriate or suitable. A letter of medical necessity confirming that Jakafi and all NCCN Category 2A alternatives are not appropriate considering organ involvement, severity, prior treatment history, comorbidities, and institutional experience must be submitted. |
| Coverage stance | Policy detail |
|---|---|
| Experimental/Investigational — not acceptable as step therapy | Treatment with an additional or different gene or cellular therapy after prior exposure to any gene or cellular therapy is considered experimental and investigational due to lack of evidence demonstrating anticipated clinical benefit, safety of sequential administration, and justification for a second intervention. Examples include switching between CAR‑T products, switching between autologous and allogeneic cellular therapies, sequential CAR‑T/TCR‑T/NK‑cell therapies, receiving gene therapy after prior vector‑based therapy, and receiving an in vivo gene therapy following prior vector‑based therapy. Individuals previously receiving any autologous cellular therapy, any allogeneic genetically modified cellular therapy, any in vivo gene therapy (e.g., AAV, lentiviral), or any ex vivo gene‑modified cell product are generally not eligible for additional gene or cellular therapy without documented evidence supporting safety and anticipated benefit. |
Quantity and Dosage Limits
Site-of-Care and Administration
PA applies regardless of infusion site (inpatient or outpatient)
Prior authorization is required regardless of whether the drug is administered inpatient or outpatient; requests for drugs administered by a healthcare professional must include PA documentation.
- Drugs administered by a healthcare professional are covered under the medical benefit unless otherwise indicated.
- The requested site of care may impact approval timeframe and is subject to review.
Definitions and Clinical Terms
Background
Ryoncil (remestemcel‑l‑rknd) is an allogeneic bone marrow‑derived mesenchymal stromal cell therapy approved for the treatment of pediatric steroid‑refractory acute graft‑versus‑host disease (SR‑aGVHD) following allogeneic hematopoietic stem cell transplantation in patients aged 2 months through 17 years. Acute GVHD commonly affects the skin, gastrointestinal tract, and liver; steroids are first‑line therapy, and the pivotal trial supporting approval reported an overall response rate of approximately 70% (n=54) in pediatric patients.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.